表紙
市場調査レポート

医薬品業界リーダーシリーズ - バイオシミラー製造メーカートップ25社 2016年〜2026年

Pharma Leader Series - 25 Top Biosimilar Drug Manufacturers 2016-2026: And Other Rising Companies - A Market Report Assessing Developers and Producers of Those Competitor Biologics

発行 Visiongain Ltd 商品コード 288682
出版日 ページ情報 英文 231 Pages
納期: 即日から翌営業日
価格
本日の銀行送金レート: 1GBP=136.36円で換算しております。

ご注意:
Single UserとDepartmentalライセンスは、DRM (デジタル著作権管理システム) 付PDFになります。
制限内容は、上記ライセンスの[?]アイコンをクリックしてご確認ください。

Back to Top
医薬品業界リーダーシリーズ - バイオシミラー製造メーカートップ25社 2016年〜2026年 Pharma Leader Series - 25 Top Biosimilar Drug Manufacturers 2016-2026: And Other Rising Companies - A Market Report Assessing Developers and Producers of Those Competitor Biologics
出版日: 2016年04月14日 ページ情報: 英文 231 Pages
概要

バイオシミラー業界には巨大な機会が残されており、2016〜2026年にかけ急速に市場が拡大するものとみられています。

当レポートでは、世界のバイオシミラー市場の概要と2026年までの予測、国別動向、およびトップ企業25社のプロファイルなどをまとめています。

第1章 レポートの概要

第2章 世界のバイオシミラー市場:2016〜2026年

  • 生物製剤とバイオシミラーのイントロダクション
    • 生物製剤:定義と概要
    • バイオシミラー:定義と概要
    • バイオシミラーとジェネリック医薬品の違い
  • 世界のバイオシミラー市場:2015〜2026年
  • 世界のバイオシミラー市場全体の収益予測:2016〜2026年
  • バイオシミラー:市場促進因子
  • バイオシミラー:市場阻害因子

第3章 主要バイオシミラー製品:概要

  • Humira:製品概要
  • Remicade:製品概要
  • Enbrel:製品概要
  • Aranesp:製品概要
  • Rituxan:製品概要

第4章 バイオシミラー主要製造メーカー:米国、西欧、イスラエル

  • Sandoz
  • Teva Pharmaceuticals
  • Hospira
  • STADA Arzneimittel
  • Mylan
  • その他のバイオシミラー製造メーカー:米国
    • Impax Laboratories Inc.
    • Bristol-Myers Squibb
    • Merck. Co.
    • Eli Lilly
  • その他のバイオシミラー製造メーカー:欧州
    • BioXpress Therapeutics
    • Medice Arzneimittel Putter GmbH. Co. KG
    • Finox Biotech
    • Actavis

第5章 バイオシミラー主要製造メーカー:中国

  • S3Bio
  • Qilu Pharmaceutical
  • Shanghai Fosun Pharmaceuticals
  • Tonghua Dongbao
  • Beijing ShuangLu Pharmaceutical
  • その他のバイオシミラー製造メーカー
    • Shanghai CP Guojian
    • Zhejiang Hisun
    • Innovent Biologics
    • Shanghai Celgen Biopharmaceutical

第6章 バイオシミラー主要製造メーカー:インド

  • Biocon
  • Dr. Reddy's Laboratories
  • Wockhardt
  • Zydus Cadila
  • Ranbaxy
  • Reliance Life Sciences
  • Intas Biopharmaceuticals
  • その他のバイオシミラー製造メーカー
    • Emcure Pharmaceuticals
    • Shreya Life Sciences
    • Cipla
    • Shantha Biotechnics

第7章 バイオシミラー主要製造メーカー:ラテンアメリカ

  • Probiomed
  • Biosidus
  • Amega Biotech
  • その他のバイオシミラー製造メーカー
    • Bionovis
    • Orygen Biotecnologia
    • Recepta

第8章 バイオシミラー主要製造メーカー:その他地域

  • Celltrion
  • LG Life Sciences
  • Dong-A
  • Bioton
  • Biocad
  • その他のバイオシミラー製造メーカー
    • Gedeon-Richter
    • Egis Pharmaceuticals
    • JCRファーマ
    • 日本化薬
    • 協和キリン富士フイルムバイオロジクス
    • 第一三共

第9章 バイオシミラー市場の定性分析

  • SWOT分析
  • STEP分析

第10章 専門家の意見

第11章 結論

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: PHA0108

Biosimilar Drug Producers - Your 2016 Guide to Companies' Activities and Prospects

Who are the most important and promising biosimilar drug companies? And what are their sales potentials? Discover, in our updated survey, organisations' outlooks from 2016. There you see results, trends, opportunities and revenue forecasting.

Visiongain's new study analyses 25 leading developers, producers and marketers of biosimilars. That work also covers other firms, including big pharma companies entering that industry. There you assess potentials of established competitors and emerging players.

Our analysis is for everyone interested in the future of biopharma. Biosimilar drug sales expand fast, and that market holds great potential, especially after opening of the US market. See now how you could benefit your plans, decisions and authority.

Forecasts and other data to help you stay ahead in knowledge on those biological drugs

In our updated report you find analytical profiles of 25 leading biosimilar drug companies. There you analyse products, sales results, R&D and prospects. See qualitative analyses, too, for those biologics, also with discussions of many other relevant firms.

Our study gives you 115 tables, 11 charts and three interviews with companies. That survey lets you assess the most lucrative parts of the industry for biosimilar drugs (follow-on biologics or subsequent entry biologics). Explore the future of those therapeutic proteins for human medicine and assess their producers.

So explore changes affecting the biological drugs industry from 2016. The following sections outline what you get in our new investigation, showing how it can help your work.

Molecules giving rise to biosimilars - explore where progress occurs

First our report discusses biosimilar competition for these five therapeutic agents - products and research and development:

  • Adalimumab
  • Infliximab
  • Etanercept
  • Darbepoetin alpha
  • Rituximab.

Large opportunities remain for biosimilars, with our study predicting high, rapid market expansion from 2016 to 2026. See what is possible. And discover where the best prospects exist and which companies are most likely to prosper.

That way you gain data and other knowledge to benefit your reputation for commercial insight. Assess products, technologies, activities and top biosimilar companies' potentials.

Leading biosimilar drug companies - see what they are doing, including their prospects

In particular our survey analyses 25 leading biosimilar specialists worldwide. First of all, Chapter 4 gives profiles of leading biosimilar companies based in the US, Western Europe and Israel:

  • Sandoz
  • Teva Pharmaceutical Industries
  • Hospira
  • STADA Arzneimittel
  • Mylan.

Chapter 5 profiles leading companies in China:

  • 3SBio
  • Qilu Pharmaceutical
  • Shanghai Fosun Pharmaceutical Group
  • Tonghua Dongbao Pharmaceutical Co.
  • Beijing ShuangLu Pharmaceutical Co.

Chapter 6 profiles leading companies in India:

  • Biocon
  • Dr. Reddy's Laboratories
  • Wockhardt
  • Zydus Cadila
  • Ranbaxy
  • Reliance Life Sciences
  • Intas Biopharmaceuticals.

Chapter 7 profiles leading companies in Latin America:

  • Probiomed
  • Biosidus
  • Amega Biotech.

Chapter 8 profiles leading companies in the rest of the world:

  • Celltrion
  • LG Life Sciences
  • Dong-A
  • Bioton
  • Biocad.

Our report also reviews 25 other companies rising in importance. See what is possible from 2016, discovering what leading companies do and their commercial outlooks.

With our survey you explore who and what shapes the biosimilars industry, including policies and other forces influencing those companies and their market, affecting its revenues and profits. Discover what the future holds for leading organisations.

Issues affecting developers, producers and sellers of those biopharmaceuticals

Our investigation explains influences and events affecting the biosimilars industry and market from 2016, including these forces:

  • Companies' technologies, strategies, collaborations, products, R&D and results
  • Emerging national markets and expanding therapeutic needs worldwide
  • Big pharma entering that market - a trend shaping that industry.

And you assess these effects, among others:

  • Patent expiries and resulting opportunities for follow-on products
  • Innovative biologics, including biobetters, and their influence on biosimilar sales
  • R&D for that market - assess technologies, clinical trials and opportunities, seeing how leading biosimilars companies adapt and progress.

There you examine political, economic, social and technological questions, assessing commercial outlooks. And you assess strengths, weaknesses, opportunities and threats affecting biosimilar drug companies' activities and results.

Developing and developed national markets will prove important for biosimilar drug sales from 2016 to 2026. Discover what the future holds and the expected gains, including overall world revenue forecasting to 2026 for the biosimilars industry.

5 Ways Pharma Leader Series: 25 Top Biosimilar Drug Manufacturers 2016-2026 helps you

Our new study helps your research, plans and analyses in these five main ways:

  • Profiles of 25 leading biosimilar companies and other relevant firms - assess products, results, strategies, technologies and outlooks, also gaining company level revenue forecasting for five leading producers' biosimilar drug sales
  • R&D for biosimilars - see activities by company, finding what goes on in that industry, investigating its technological and commercial potentials
  • Competition and opportunities - explore what affects the biosimilars market, finding what shapes its future, especially prospects for developing business
  • Interviews with 3 companies - discover views to help you stay ahead in knowledge on that expanding drugs market
  • Revenue forecasting to 2026 for that industry at world level - investigate overall sales potential there, seeing what revenue gains are possible.

Analysis found nowhere else, letting you explore the future of those biologics

Our work - by visiongain's UK-based analysts - gives you independent research and analysis. There you get a review of that industry and data found only in our report. You explore the most promising market segments and assess leading companies' prospects.

With that investigation you are less likely to fall behind in knowledge. See how you could benefit your research, analysis and decisions. Also discover how you could save time and gain in recognition for insight on the biological drugs market, helping your influence.

Predictions for developing, producing and selling biosimilars - see now what is possible

Our updated study shows you data, trends, opportunities and outlooks for producers and sellers of biosimilars and related medicines. That analysis is for everybody interested in the future of biopharmaceuticals. So avoid missing out - instead please get our report here now.

visiongain is a trading partner with the US Federal Government.

Table of Contents

1. Report Overview

  • 1.1. Overview of the Top Biosimilar Drug Manufacturers
  • 1.2. Why You Should Read This Report
  • 1.3. How This Report Delivers
  • 1.4. Main Questions Answered by This Analytical Study
  • 1.5. Who is This Report For?
  • 1.6. Methodology
  • 1.7. Frequently Asked Questions (FAQ)
  • 1.8. Associated Visiongain Reports
  • 1.9. About Visiongain

2. Biosimilar Drugs: World Market Forecast, 2016-2026

  • 2.1. Introduction to Biologics and Biosimilars
    • 2.1.1. Biologic Drugs Definition and Overview
    • 2.1.2. Biosimilars Drugs Definition and Overview
    • 2.1.3. How do Biosimilars Differ from Generics?
  • 2.2. The World Biosimilar Market, 2015-2026
  • 2.3. Overall World Biosimilars Revenue Forecast, 2016-2026
  • 2.4. Biosimilars-Realising their Potential, Market Drivers
    • 2.4.1. Biosimilar Approval Pathways and Regulations
    • 2.4.2. Emerging Markets for Biosimilars
    • 2.4.3. Start-up Pressure on Market Leaders
    • 2.4.4. The Patent Cliff for Biologics
  • 2.5. Biosimilars: Market Restraints
    • 2.5.1. Market Fragmentation for Biosimilar Products
    • 2.5.2. Innovative Biologics-Rendering Biosimilars Useless?
    • 2.5.3. Biobetters-A Growing Threat

3. Leading Biosimilar Products: Overview, 2016

  • 3.1. Humira: Product Overview
    • 3.1.1. Adalimumab Biosimilars-Zydus Cadila
    • 3.1.2. Adalimumab Biosimilars-Amgen-Actavis
    • 3.1.3. Adalimumab Biosimilars-Sandoz
    • 3.1.4. Adalimumab Biosimilars-Momenta Pharmaceuticals
    • 3.1.5. Adalimumab Biosimilars-Pfizer
    • 3.1.6. Adalimumab Biosimilars-Boehringer Ingelheim
  • 3.2. Remicade: Product Overview
    • 3.2.1. Infliximab Biosimilar-Epirus Pharmaceuticals. Ranbaxy
    • 3.2.2. Infliximab Biosimilar-Celltrion. Hospira. Alvogen
  • 3.3. Enbrel: Product Overview
    • 3.3.1. Etanercept Biosimilar-Cipla. Shanghai CP Guojian
    • 3.3.2. Etanercept Biosimilar-Daiichi Sankyo. Coherus Biosciences
  • 3.4. Aranesp: Product Overview
    • 3.4.1. Darbepoetin Alpha Biosimilar-Dr. Reddy's Laboratories
    • 3.4.2. Darbepoetin Alpha Biosimilar-Cipla. Hetero Drugs Limited
    • 3.4.3. Darbepoetin Alpha Biosimilar-Hospira
  • 3.5. Rituxan: Product Overview
    • 3.5.1. Rituximab Biosimilar-Sandoz
    • 3.5.2. Rituximab Biosimilar-Amgen
    • 3.5.3. Rituximab Biosimilar-Boehringer Ingelheim
    • 3.5.4. Rituximab Biosimilar-Dr. Reddy's Laboratories
    • 3.5.5. Rituximab Biosimilar-Pfizer
    • 3.5.6. Rituximab Biosimilar-Difficulties Seen in Trials

4. Leading Biosimilar Manufacturers in the United States, Western Europe and Israel, 2016

  • 4.1. Sandoz-Company Overview. Analysis
    • 4.1.1. Sandoz Biosimilar Products
    • 4.1.2. Sandoz Biosimilars Market Forecast, 2016-2026
    • 4.1.3. Sandoz Biosimilars R&D Pipeline. Future Outlook
      • 4.1.3.1. GP2017-Adalimumab Biosimilar
      • 4.1.3.2. GP2015-Etanercept Biosimilar
      • 4.1.3.3. GP2013-Rituximab Biosimilar
      • 4.1.3.4. HX575-Epoetin-alfa Biosimilar
      • 4.1.3.5. EP2006-Zarzio (Filgrastim Biosimilar)
  • 4.2. Teva Pharmaceuticals-Company Overview. Analysis
    • 4.2.1. Teva Biosimilar Products
    • 4.2.2. Teva Biosimilar Market Forecast, 2016-2026
    • 4.2.3. Teva Biosimilar Pipeline. Future Outlook
  • 4.3. Hospira-Company Overview. Analysis
    • 4.3.1. Hospira Biosimilar Products
    • 4.3.2. Hospira Biosimilars Pipeline. Future Strategies
      • 4.3.2.1. Retacrit
      • 4.3.2.2. Celltrion Partnerships
      • 4.3.2.3. NovaQuest Partnership
  • 4.4. STADA Arzneimittel-Company Overview. Analysis
    • 4.4.1. STADA Biosimilar Products
    • 4.4.2. STADA Biosimilars Pipeline. Future Outlook
      • 4.4.2.1. Biosimilar Pegfilgrastim
      • 4.4.2.2. Biosimilar Rituximab
      • 4.4.2.3. Biosimilar Teriparatide
  • 4.5. Mylan-Company Biosimilar. Analysis
    • 4.5.1. Mylan Biosimilar Products
    • 4.5.2. Mylan Biosimilar Market Forecast, 2016-2026
    • 4.5.3. Mylan Biosimilars Pipeline. Future Outlook
      • 4.5.3.1. Mylan and Momenta. Biosimilars Product Development Programme
      • 4.5.3.2. Biosimilar Insulin Glargine
      • 4.5.3.3. A Series of Biosimilar Monoclonal Antibodies
      • 4.5.3.4. Biosimilar Insulin Lispro. Aspart
  • 4.6. Other Biosimilars Companies in the US
    • 4.6.1. Impax Laboratories Inc.-Company Overview. Analysis
    • 4.6.2. Bristol-Myers Squibb-Company Overview. Analysis
    • 4.6.3. Merck. Co.-Company Overview. Analysis
    • 4.6.4. Eli Lilly. Company Overview. Analysis
  • 4.7. Other Biosimilars Companies in Europe
    • 4.7.1. BioXpress Therapeutics-Company Overview. Analysis
    • 4.7.2. Medice Arzneimittel Pütter GmbH. Co. KG-Company Overview. Analysis
    • 4.7.3. Finox Biotech-Company Overview. Analysis
    • 4.7.4. Actavis-Company Overview. Analysis

5. Leading Biosimilar Manufacturers in China, 2016

  • 5.1. S3Bio-Company Overview. Analysis
    • 5.1.1. 3SBio Biosimilar Products
    • 5.1.2. 3SBio Biosimilars Market Forecast, 2016-2026
    • 5.1.3. 3SBio Biosimilars Pipeline. Future Outlook
      • 5.1.3.1. Second-generation rhEPO products
      • 5.1.3.2. Nadroparin Calcium
  • 5.2. Qilu Pharmaceutical-Company Overview. Analysis
    • 5.2.1. Qilu Pharmaceutical Biosimilar Products
    • 5.2.2. Qilu Pharmaceutical Biosimilars Pipeline. Future Outlook
      • 5.2.2.1. Extensive Pipeline Developments
      • 5.2.2.2. Etanercept Biosimilar
      • 5.2.2.3. Other Biosimilars in Pipeline
  • 5.3. Shanghai Fosun Pharmaceuticals-Company Overview. Analysis
    • 5.3.1. Shanghai Fosun Pharmaceuticals Biosimilar Products
    • 5.3.2. Shanghai Fosun Pharmaceuticals Biosimilars Pipeline. Future Strategy
      • 5.3.2.1. Trastuzumab Biosimilar
      • 5.3.2.2. Rituximab Biosimilar
      • 5.3.2.3. Acquisitions and Investments
  • 5.4. Tonghua Dongbao-Company Overview. Analysis
    • 5.4.1. Tonghua Dongbao Biosimilar Products
    • 5.4.2. Tonghua Dongbao Biosimilars Pipeline. Future Strategies
      • 5.4.2.1. Biosimilar Insulin Analogues
      • 5.4.2.2. Investments in New Production Plant
  • 5.5. Beijing ShuangLu Pharmaceuticals-Company Overview. Analysis
    • 5.5.1. Beijing ShuangLu Pharmaceuticals Biosimilar Products
    • 5.5.2. Beijing ShuangLu Pharmaceutical Biosimilars Pipeline. Future Outlook
  • 5.6. Other Biosimilars Companies in China
    • 5.6.1. Shanghai CP Guojian-Company Overview. Analysis
    • 5.6.2. Zhejiang Hisun-Company Overview. Analysis
    • 5.6.3. Innovent Biologics-Company Overview. Analysis
    • 5.6.4. Shanghai Celgen Biopharmaceutical-Company Overview. Analysis

6. Leading Biosimilar Manufacturers in India, 2016

  • 6.1. Biocon-Company Overview. Analysis
    • 6.1.1. Biocon Biosimilar Products
    • 6.1.2. Biocon Biosimilars Market Forecast, 2016-2026
    • 6.1.3. Biocon Biosimilars Pipeline. Future Outlook
      • 6.1.3.1. Biosimilar Bevacizumab
      • 6.1.3.2. Biosimilar Adalimumab
      • 6.1.3.3. Biosimilar Pegfilgrastim
      • 6.1.3.4. Biosimilar Trastuzumab
      • 6.1.3.5. Biosimilar Etanercept
      • 6.1.3.6. Biosimilar Recombinant Human Insulin
      • 6.1.3.7. Biosimilar Insulin Glargine
      • 6.1.3.8. Other Biosimilar Insulin
  • 6.2. Dr. Reddy's Laboratories-Company Overview. Analysis
    • 6.2.1. Dr. Reddy's Laboratories Biosimilar Products
    • 6.2.2. Dr. Reddy's Laboratories Biosimilars Pipeline. Future Outlook
      • 6.2.2.1. Merck Serono Collaboration
      • 6.2.2.2. Increasing Focus on Emerging Markets
  • 6.3. Wockhardt-Company Overview. Analysis
    • 6.3.1. Wockhardt Biosimilar Products
    • 6.3.2. Wockhardt Biosimilars Pipeline. Future Outlook
  • 6.4. Zydus Cadila-Company Overview. Analysis
    • 6.4.1. Zydus Cadila Biosimilar Products
    • 6.4.2. Zydus Cadila Biosimilars Pipeline. Future Outlook
      • 6.4.2.1. Biosimilar Interferon beta-1b
      • 6.4.2.2. Oncology Biosimilars
      • 6.4.2.3. Inflammation Biosimilars
      • 6.4.2.4. Thrombolytic Biosimilars
      • 6.4.2.5. Fertility Biosimilars
  • 6.5. Ranbaxy-Company Overview. Analysis
    • 6.5.1. Ranbaxy Biosimilar Products
    • 6.5.2. Ranbaxy Biosimilars Pipeline. Future Outlook
  • 6.6. Reliance Life Sciences-Company Overview. Analysis
    • 6.6.1. Reliance Life Sciences Biosimilar Products
    • 6.6.2. Reliance Life Sciences Biosimilars Pipeline. Future Outlook
  • 6.7. Intas Biopharmaceuticals-Company Overview. Analysis
    • 6.7.1. Intas Biopharmaceuticals Biosimilar Products
    • 6.7.2. Intas Biopharmaceuticals Biosimilars Pipeline. Future Outlook
      • 6.7.2.1. Biosimilar Pegylated Interferon
      • 6.7.2.2. Biosimilar Etanercept
      • 6.7.2.3. Biosimilar Ranibizumab
      • 6.7.2.4. Overseas Opportunities
  • 6.8. Other Indian Biosimilars Companies
    • 6.8.1. Emcure Pharmaceuticals-Company Overview. Analysis
    • 6.8.2. Shreya Life Sciences-Company Overview. Analysis
    • 6.8.3. Cipla-Company Overview. Analysis
    • 6.8.4. Shantha Biotechnics-Company Overview. Analysis

7. Leading Biosimilar Manufacturers in Latin America, 2016

  • 7.1. Probiomed-Company Overview. Analysis
    • 7.1.1. Probiomed Biosimilar Products
    • 7.1.2. Probiomed Biosimilars Pipeline. Future Strategies
  • 7.2. Biosidus-Company Overview. Analysis
    • 7.2.1. Biosidus Biosimilar Products
    • 7.2.2. Biosidus Biosimilars Pipeline. Future Strategies
  • 7.3. Amega Biotech-Company Overview and Analysis
    • 7.3.1. Amega-Biosimilar Products
    • 7.3.2. Amega Biotech Biosimilars Pipeline. Future Strategies
  • 7.4. Other Biosimilars Companies in South America
    • 7.4.1. Bionovis-Company Overview. Analysis
    • 7.4.2. Orygen Biotecnologia-Company Overview. Analysis
    • 7.4.3. Recepta-Company Overview. Analysis

8. Leading Biosimilar Manufacturers in the Rest of the World, 2016

  • 8.1. Celltrion-Company Overview. Analysis
    • 8.1.1. Celltrion Biosimilar Products
    • 8.1.2. Celltrion Biosimilars Pipeline. Future Strategies
      • 8.1.2.1. Trastuzumab Biosimilar
      • 8.1.2.2. Rituximab Biosimilar
      • 8.1.2.3. Four Further Development mAb Biosimilar
  • 8.2. LG Life Sciences-Company Overview. Analysis
    • 8.2.1. LG Life Sciences Biosimilar Products
    • 8.2.2. LG Life Science Biosimilars Pipeline. Future Strategies
  • 8.3. Dong-A-Company Overview. Analysis
    • 8.3.1. Dong-A Biosimilar Products
    • 8.3.2. Dong-A Biosimilars Pipeline. Future Strategies
      • 8.3.2.1. DA-3803-hCG Biosimilar
      • 8.3.2.2. DA-3031-Pegylated Filgrastim Biosimilar
      • 8.3.2.3. DA-3880-Darbepoetin Alpha Biosimilar
      • 8.3.2.4. DA-3111-Trastuzumab Biosimilar
      • 8.3.2.5. DA-3113-Adalimumab Biosimilar
      • 8.3.2.6. 3853-Etanercept Biosimilar
    • 8.3.2.7. DA-3808-Recombinant Factor VIII Biosimilar
  • 8.4. Bioton-Company Overview. Analysis
    • 8.4.1. Bioton's Biosimilar Products
    • 8.4.2. Bioton's Biosimilars Pipeline. Future Strategies
  • 8.5. Biocad-Company Overview. Analysis
    • 8.5.1. Biocad's Biosimilar Products
    • 8.5.2. Biocad's Biosimilars Pipeline. Future Strategies
  • 8.6. Other Biosimilars Companies in the RoW
    • 8.6.1. Gedeon-Richter-Company Overview. Analysis
    • 8.6.2. Egis Pharmaceuticals. Company Overview. Analysis
    • 8.6.3. JCR Pharmaceuticals-Company Overview. Analysis
    • 8.6.4. Nippon Kayaku-Company Overview. Analysis
    • 8.6.5. Fujifilm Kyowa Kirin Biologics-Company Overview. Analysis
    • 8.6.6. Daiichi Sankyo-Company Overview. Analysis

9. Qualitative Analysis of Biosimilars Market, 2016-2026

  • 9.1. SWOT Analysis of the Global Biosimilars Industry and Market, 2016-2026
    • 9.1.1. Strengths
      • 9.1.1.1. Savings in Healthcare Costs
      • 9.1.1.2. Strong Pipeline-Innovation and Growth of the Biosimilars Market
      • 9.1.1.3. Entry of Biosimilars Into the US market
    • 9.1.2. Weaknesses
      • 9.1.2.1. R&D Cost-Pricing Companies Out of Biosimilars?
      • 9.1.2.2. Developing Market-Biosimilars Still Niche
      • 9.1.2.3. Unclear Regulations for Biosimilars
    • 9.1.3. Opportunities
      • 9.1.3.1. Patent Expiry for Branded Biologics
      • 9.1.3.2. Increase in Prevalence of Chronic Diseases
      • 9.1.3.3. Innovation-New Technology Driving Biosimilar Growth
      • 9.1.3.4. Focus on Biosimilar Monoclonal Antibodies and Insulin
    • 9.1.4. Threats
      • 9.1.4.1. Stricter Regulations for Biosimilar Manufacturers
      • 9.1.4.2. Lawsuits-Patent Protection from Innovator Biologics
      • 9.1.4.3. Biobetters. Removing the Need for Biosimilars?
  • 9.2. STEP Analysis of the Global Biosimilars Industry and Market: 2016-2026
    • 9.2.1. Social Factors
      • 9.2.1.1. Global Healthcare-An Ambitious Aim?
      • 9.2.1.2. Raising Awareness will Lead to Greater Product Adoption
    • 9.2.2. Technological Factors
      • 9.2.2.1. Innovation Driven-Growing Manufacturing Efficiency
      • 9.2.2.2. High Technological Expertise Needed
    • 9.2.3. Economic Factors
      • 9.2.3.1. R&D for Biosimilar Development-Cost Barriers
      • 9.2.3.2. Healthcare Savings-Cutting Spending and Costs
    • 9.2.4. Political Factors
      • 9.2.4.1. Government Influence-Funding for Biosimilar Industry?
      • 9.2.4.2. International Cooperation Required
      • 9.2.4.3. Regularly Updated Guideline Will Benefit Developers

10. Research Interviews

  • 10.1. Mr Chandru Chawla, Head of Corporate Strategy, Cipla
    • 10.1.1. Cipla Overview
    • 10.1.2. Introducing Cipla's Biosimilars Landscape
    • 10.1.3. Cipla's Biosimilars Strategy: Collaboration. Competition
    • 10.1.4. Future Directions for the Biosimilars Industry
  • 10.2. Mr Peter Keller, Chief Business Officer, Selecta Bioscience
    • 10.2.1. Novel Technology Platform
    • 10.2.2. Application with Drugs
    • 10.2.3. Biosimilar Vaccines-Future Potential?
    • 10.2.4. Future Strategies
    • 10.2.5. Biosimilar Market Outlook
  • 10.3. Industry Source from. Leading Indian Biopharmaceutical Company
    • 10.3.1. Indian Pharmaceutical and Biosimilars Market Overview
    • 10.3.2. Indian Patent Protection-Effect on Biosimilar Industry
    • 10.3.3. Partnerships among Biosimilar Companies
    • 10.3.4. Future Developments in the Indian Biosimilars Market

11. Conclusions

  • 11.1. Market Leaders Among Biosimilar Manufacturers
  • 11.2. Will Sandoz Retain its Position as Market Leader?
  • 11.3. Which Companies Are Best Placed to Lead in Future?
  • 11.4. Big Pharma Companies Will Try Gain Market Entry
  • 11.5. Contribution of Chinese and Indian Companies will Grow
  • 11.6. Strong R&D Pipeline-Driver for Growth
  • 11.7. Concluding Remarks

List of Tables

  • Table 2.1: Global Biosimilar Market: Revenue Forecast ($bn), Annual Growth (%), CAGR (%), 2015-2020
  • Table 2.2: Global Biosimilar Market: Revenue Forecast ($bn), Annual Growth (%), CAGR (%), 2021-2026
  • Table 3.1: Humira Biologic Analysis, 2016
  • Table 3.2: Remicade Biologic Analysis, 2016
  • Table 3.3: Enbrel Biologic Analysis, 2016
  • Table 3.4: Aranesp: Biologic Analysis, 2016
  • Table 3.5: Rituxan: Biologic Analysis, 2016
  • Table 4.1: Sandoz: Company Overview, 2016
  • Table 4.2: Sandoz: Biosimilar Product Portfolio, 2016
  • Table 4.3: Sandoz: Biosimilar Products Forecast: Revenue ($bn), AGR (%), CAGR (%), 2015-2020
  • Table 4.4: Sandoz: Biosimilar Products Forecast: Revenue ($bn), AGR (%), CAGR (%), 2021-2026
  • Table 4.5: Sandoz: Biosimilar Developments Overview, 2016
  • Table 4.6: Teva: Company Overview, 2016
  • Table 4.7: Teva: Biosimilar Developments Overview, 2016
  • Table 4.8: Teva Pharmaceuticals: Biosimilar Products Forecast: Revenue ($bn), AGR (%), CAGR (%), 2015-2020
  • Table 4.9: Teva Pharmaceuticals: Biosimilar Products Forecast: Revenue ($bn), AGR (%), CAGR (%), 2021-2026
  • Table 4.10: Hospira: Company Overview, 2016
  • Table 4.11: Hospira: Biosimilars Overview, 2016
  • Table 4.12: Hospira: Biosimilar Developments Overview, 2016
  • Table 4.13: Stada Arzneimittel: Company Overview, 2016
  • Table 4.14: Stada Arzneimittel: Biosimilars Overview, 2016
  • Table 4.15: Stada Arzneimittel: Biosimilar Developments Overview, 2016
  • Table 4.16: Mylan: Company Overview, 2016
  • Table 4.17: Mylan: Biosimilars Overview, 2016
  • Table 4.18: Mylan Pharmaceuticals: Biosimilar Products Forecast: Revenue ($bn), AGR (%), CAGR (%), 2015-2020
  • Table 4.19: Mylan Pharmaceuticals: Biosimilar Products Forecast: Revenue ($bn), AGR (%), CAGR (%), 2021-2026
  • Table 4.20: Mylan: Biosimilar Developments Overview, 2016
  • Table 4.21: Impax Laboratories: Company Overview, 2016
  • Table 4.22: Bristol-MyersSquibb: Company Overview, 2016
  • Table 4.23: Merck & Co.: Company Overview, 2016
  • Table 4.24: Merck & Co.: Biosimilars Product Pipeline, 2016
  • Table 4.25: Eli Lilly: Company Overview, 2016
  • Table 4.26: Eli Lilly: Biosimilars Product Portfolio, 2016
  • Table 4.27: BioXpress Therapeutics: Company Overview, 2016
  • Table 4.28: Medice Arzneimittel Pütter: Company Overview, 2016
  • Table 4.29: Finox Biotech: Company Overview, 2016
  • Table 4.30: Actavis: Company Overview, 2016
  • Table 5.1: 3SBio: Company Overview, 2016
  • Table 5.2: 3SBio: Biosimilars Overview, 2016
  • Table 5.3: 3SBio Pharmaceuticals: Biosimilar Products Forecast: Revenue ($bn), AGR (%), CAGR (%), 2015-2020
  • Table 5.4: 3SBio Pharmaceuticals: Biosimilar Products Forecast: Revenue ($bn), AGR (%), CAGR (%), 2021-2026
  • Table 5.5: 3SBio: Biosimilar Developments Overview, 2016
  • Table 5.6: Qilu Pharmaceutical: Company Overview, 2016
  • Table 5.7: Qilu Pharmaceutical: Biosimilars Overview, 2016
  • Table 5.8: Qilu Pharmaceutical: Biosimilar Developments Overview, 2016
  • Table 5.9: Shanghai Fosun: Company Overview, 2016
  • Table 5.10: Shanghai Fosun: Biosimilars Overview, 2016
  • Table 5.11: Shanghai Fosun: Biosimilar Developments Overview, 2016
  • Table 5.12: Tonghua Dongbao: Company Overview, 2016
  • Table 5.13: Tonghua Dongbao: Biosimilars Overview, 2016
  • Table 5.14: Tonghua Dongbao: Biosimilar Developments Overview, 2016
  • Table 5.15: Beijing ShuangLu: Company Overview, 2016
  • Table 5.16: Beijing ShuangLu: Biosimilars Overview, 2016
  • Table 5.17: Beijing ShuangLu: Biosimilar Developments Overview, 2016
  • Table 5.18: Shanghai CP Guojian: Company Overview, 2016
  • Table 5.19: Zhejiang Hisun: Company Overview, 2016
  • Table 5.20: Innovent Biologics: Company Overview, 2016
  • Table 5.21: Shanghai Celgen Biopharmaceutical: Company Overview, 2016
  • Table 6.1: Biocon: Company Overview, 2016
  • Table 6.2: Biocon: Biosimilars Product Portfolio, 2016
  • Table 6.3: Biocon: Biosimilar Products Forecast: Revenue ($bn), AGR (%), CAGR (%), 2015-2020
  • Table 6.4: Biocon: Biosimilar Products Forecast: Revenue ($bn), AGR (%), CAGR (%), 2021-2026
  • Table 6.5: Biocon: Biosimilars Pipeline, 2016
  • Table 6.6: Dr. Reddy's Laboratories: Company Overview, 2016
  • Table 6.7: Dr. Reddy's Laboratories: Biosimilar Products, 2016
  • Table 6.8: Dr. Reddy's Laboratories: Biosimilars Pipeline, 2016
  • Table 6.9: Wockhardt: Company Overview, 2016
  • Table 6.10: Wockhardt: Biosimilar Products, 2016
  • Table 6.11: Wockhardt: Biosimilars Pipeline, 2016
  • Table 6.12: Zydus Cadila: Company Overview, 2016
  • Table 6.13: Zydus Cadila: Biosimilars Product Portfolio, 2016
  • Table 6.14: Zydus Cadila: Biosimilars Pipeline, 2016
  • Table 6.15: Ranbaxy: Company Overview, 2016
  • Table 6.16: Ranbaxy: Biosimilars Product Portfolio, 2016
  • Table 6.17: Zenotech: Biosimilars Pipeline, 2016
  • Table 6.18: Reliance Life Sciences: Company Overview, 2016
  • Table 6.19: Reliance Life Sciences: Biosimilar Products, 2016
  • Table 6.20: Reliance Life Sciences: Biosimilars Pipeline, 2016
  • Table 6.21: Intas Biopharmaceuticals: Company Overview, 2016
  • Table 6.22: Intas Biopharmaceuticals: Biosimilar Products Portfolio, 2016
  • Table 6.23: Intas Biopharmaceuticals: Biosimilars Pipeline, 2016
  • Table 6.24: Emcure Pharmaceuticals: Company Overview, 2016
  • Table 6.25: Shreya Life Sciences: Company Overview, 2016
  • Table 6.26: Cipla: Company Overview, 2016
  • Table 6.27: Shantha Biotechnics: Company Overview, 2016
  • Table 7.1: Probiomed: Company Overview, 2016
  • Table 7.2: Probiomed Biosimilars Product Portfolio, 2016
  • Table 7.3: Biosidus: Company Overview, 2016
  • Table 7.4: Biosidus: Biosimilars Product Portfolio, 2016
  • Table 7.5: Biosidus: Biosimilars Pipeline, 2016
  • Table 7.6: Amega Biotech: Company Overview, 2016
  • Table 7.7: Amega Biotech: Biosimilars Product Portfolio , 2016
  • Table 7.8: Bionovis: Company Overview, 2016
  • Table 7.9: Orygen Biotechnologia: Company Overview, 2016
  • Table 7.10: Recepta: Company Overview, 2016
  • Table 8.1: Celltrion: Company Overview, 2016
  • Table 8.2: Celltrion: Biosimilars, 2016
  • Table 8.3: Celltrion: Biosimilars Product Pipeline, 2016
  • Table 8.4: LG Life Sciences: Company Overview, 2016
  • Table 8.5: LG Life Sciences: Biosimilars Product Portfolio, 2016
  • Table 8.6: LG Life Sciences: Biosimilars Pipeline, 2016
  • Table 8.7: Dong-A: Company Overview, 2016
  • Table 8.8: Dong-A: Biosimilar Product Portfolio, 2016
  • Table 8.9: Dong-A: Biosimilar Pipeline, 2016
  • Table 8.10: Bioton: Company Overview, 2016
  • Table 8.11: Bioton: Biosimilars Product Portfolio, 2016
  • Table 8.12: Biocad: Company Overview, 2016
  • Table 8.13: Biocad: Biosimilars Product Portfolio, 2016
  • Table 8.14: Biocad: Biosimilars Pipeline, 2016
  • Table 8.15: Gedeon-Richter: Company Overview, 2016
  • Table 8.16: Egis Pharmaceuticals: Company Overview, 2016
  • Table 8.17: JCR Pharmaceuticals: Company Overview, 2016
  • Table 8.18: Nippon Kayaku: Company Overview, 2016
  • Table 8.19: Fujifilm Kyowa Kirin Biologics: Company Overview, 2016
  • Table 8.20: Daiichi Sankyo: Company Overview, 2016

List of Figures

  • Figure 1.1: Biosimilars Market Segmentation, 2016
  • Figure 2.1: Global Biosimilar Market: Revenue Forecast ($bn), 2015-2026
  • Figure 2.2: Global Biosimilar Market Drivers, 2016
  • Figure 2.3: Global Biosimilar Market Restraints, 2016
  • Figure 4.1: Sandoz: Biosimilar Products Revenue Forecast ($bn), 2015-2026
  • Figure 4.2: Teva Pharmaceuticals: Biosimilar Products Revenue Forecast ($bn), 2015-2026
  • Figure 4.3: Mylan Pharmaceuticals: Biosimilar Products Revenue Forecast ($bn), 2015-2026
  • Figure 5.1: S3Bio Pharmaceuticals: Biosimilar Products Revenue Forecast ($bn), 2015-2026
  • Figure 6.1: Biocon: Biosimilar Products Revenue Forecast ($bn), 2015-2026
  • Figure 9.1: SWOT Analysis of the Biosimilars Market, 2016
  • Figure 9.2: STEP Analysis of the Biosimilars Market, 2016

Companies Listed

  • 3SBio
  • Abbott Laboratories
  • AbbVie
  • Aché
  • Actavis
  • Adimab
  • Alvogen
  • Amega Biotech
  • Amgen
  • Apotex
  • Aragen Bioscience
  • ASKA Pharmaceuticals
  • AstraZeneca
  • Avesthagen
  • Baxter International
  • Beijing SL Pharmaceutical
  • Bio Technology General Corporation
  • Biocad
  • Bioceuticals
  • Biocon
  • Biogen Idec.
  • Biolab Sanus Farmacêutica
  • BioMab
  • Bionovis
  • BioPartners
  • Biosidus
  • Biotech GmbH
  • Biocon
  • Bioton
  • Biovel Life Sciences
  • BioXpress Therapeutics
  • Boehringer Ingelheim
  • Brazil's National Economic Development Bank (BNDES)
  • Brazilian Ministry of Health
  • Brazilian Ministry of Science and Technology (MST)
  • Bristol-Myers Squibb
  • Catalent Pharma Solutions
  • Celltrion
  • China Israel Value Capital
  • Chongqing Fochon Pharmaceutical Research Co.
  • Cipla
  • CITIC Group
  • Clinigene
  • Coherus Biosciences
  • Comisión Federal para la Protección contra Riesgos Sanitarios (Cofepris)
  • Committee for Medicinal Products for Human Use (CHMP)
  • Competitions Commission of India (CCI)
  • Cristalía
  • Daiichi Sankyo
  • Dainippon Sumitomo Pharma
  • Dong-A Pharmaceuticals
  • Dr. Reddy's Laboratories
  • Drugs Controller General of India
  • Egis Pharmaceuticals
  • Eisai
  • Eli Lilly
  • Emcure Pharmaceuticals
  • EMS
  • Epirus Pharmaceuticals
  • Eurofarma
  • European Medicines Agency (EMA)
  • Financier of Studies and Projects (FINEP)
  • Finox Biotech
  • Food and Drug Administration (FDA)
  • Forwell Biopharm
  • Fosun Pharma
  • Fuji Pharma
  • Fujifilm Kyowa Kirin Biologics
  • Gan & Lee Pharmaceutical
  • Gedeon-Richter
  • Generex Biotechnology Corporation
  • GeneScience
  • Gennova
  • Genzyme
  • German Remedies
  • Germonta Holdings
  • GlaxoSmithKline
  • Hanwha Chemical
  • Haselmeier
  • Hetero Drugs
  • Hospira
  • Hualida Biotech
  • Human Genome Sciences
  • Hypermarcas
  • Impax Laboratories
  • Indian Clinical Trials Registry (CTRI)
  • Innovent Biologics
  • Intas Biopharmaceuticals
  • Intas Pharmaceuticals
  • Itero Biopharmaceuticals
  • Janssen Biotech
  • Japan's Ministry of Health, Labour and Welfare
  • JCR Pharmaceuticals
  • Johnson & Johnson
  • Korean Food and Drug Administration (KFDA)
  • Kwizda Pharmaceutical
  • Kyowa Hakko Kirin
  • Lallemand-Institut Rosell
  • LG Life Sciences
  • Libbs Farmacêutica
  • Lonza
  • Lupin
  • MabPharm
  • Marvel Life Sciences
  • Medice Arzneimittel Pütter GmbH & Co. KG
  • MedImmune
  • Meiji Seika Pharmaceuticals
  • Merck & Co.
  • Merck KGaA
  • Merck Serono
  • Mindar Holdings
  • Mitsubishi Tanabe
  • MJ Biopharm
  • MJ Bioton Life Sciences
  • Mochida Pharmaceutical
  • Momenta Pharmaceuticals
  • Mylan
  • National Autonomous University of Mexico (UNAM)
  • National Council for Science and Technology (CONACyT)
  • Nippon Kayaku
  • NovaQuest
  • Novartis
  • Novo Nordisk
  • Orygen Biotecnologia
  • Oswaldo Cruz Foundation
  • Parexel
  • Pfenex
  • Pfizer
  • Pharmstandard
  • Pliva
  • Probiomed
  • Qilu Pharmaceutical
  • Ranbaxy
  • Ratiopharm
  • Recepta
  • Retacrit
  • Reliance Life Sciences
  • Richter-Helm BioTec GmbH & Co. KG
  • Rimsa
  • Roche
  • Samsung Bioepis
  • Samsung BioLogics
  • Sandoz
  • Sanofi
  • Savient Pharmaceuticals
  • SciGen
  • Selecta Biosciences
  • Shanghai Celgen Biopharmaceutical
  • Shanghai CP Guojian
  • Shanghai Fosun Pharmaceuticals
  • Shanghai Henlius Biotech Co.
  • Shanghai Lansheng Guojian Pharmaceutical Co. Ltd
  • Shanghai Pharmaceutical Group
  • Shantha Biotechnics
  • Shreya
  • Shreya Life Sciences
  • Sicor Biotech
  • Sidus Pharmaceutical Group
  • Simcere
  • Sinopharm
  • STADA Arzneimittel
  • State's Employees' Social Security and Social Services Institute (ISSSTE)
  • Sun Pharmaceuticals
  • Syngene
  • Synthon
  • Takeda
  • Tat BioTech Holdings Limited
  • Teva Pharmaceutical Industries
  • Tonghua Dongbao
  • União Química
  • US Centers for Disease Prevention and Control (CDC)
  • Wanbang Biopharmaceuticals
  • Wockhardt
  • World Health Organization (WHO)
  • Wyeth
  • Xiamen Amoytop Biotech
  • Ypsomed
  • Zenotech Laboratories
  • Zhejiang Hisun
  • Zuventus
  • Zydus Biovation
  • Zydus Cadila
Back to Top